Irish CRO Icon ($ICLR) has closed out its $143.5 million acquisition of Aptiv Solutions, a deal designed to amp up its technology and expand its presence in Japan. Icon has now absorbed the Reston, VA-headquartered CRO, which made its name assisting drug and device developers with planning and executing adaptive clinical trials, allowing sponsors to make data-driven decisions midstudy. Icon also gets Niphix, Aptiv's Japanese subsidiary, which focuses on work in oncology. Release